Skybiotech Healthcare Limited has released its unaudited financial results for the quarter ended December 31, 2025, marking another reporting milestone following its recent corporate transformation. The company, formerly known as Kapil Cotex Limited, conducted its board meeting on February 14, 2026, to review and approve the quarterly financial statements.

Board Meeting and Financial Approval

The Board of Directors convened on Saturday, February 14, 2026, from 5:00 PM to 6:30 PM to consider and approve the unaudited financial results for both standalone and consolidated operations. The meeting was conducted in compliance with Regulation 30(6) and 30(2) of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

The Audit Committee reviewed and recommended the financial results before the Board's final approval. The statutory auditors have issued a Limited Review Report, which has been taken on record by the Board.

Corporate Name Change Details

A significant corporate development occurred during the reporting period, with the company officially changing its name from Kapil Cotex Limited to Skybiotech Healthcare Limited. The name change process involved several key dates:

Earnings Per Share Information

The financial results include earnings per share data for continuing operations. The basic earnings per share figures show values of -0.30, 6.79, -1.03, 0.15, 7.56, and -1.50 across different periods. Similarly, the diluted earnings per share reflects the same values for continuing operations, while no earnings per share were reported for discontinuing operations during the periods under review.

Operational Structure and Compliance

The company operates as a single-segment business, with all operations relating to one primary segment. This structure means that segment reporting as defined in Accounting Standard 17 is not applicable to the company's financial reporting requirements.

The financial results have been prepared in accordance with SEBI regulations, with previous period figures regrouped where necessary for better comparability and presentation.

Company Information

Skybiotech Healthcare Limited maintains its registered office at Gut No. 05, Gevrai Tanda, Paithan Road, Chhatrapati Sambhaji Nagar (Aurangabad), Maharashtra 431002. The company continues to trade on BSE under script code 512036, with Poonam Prakash Rathi serving as Managing Director (DIN: 01274428).

Kapil Cotex Limited , a company listed on the Bombay Stock Exchange (BSE), has undergone a significant transformation with a change in its corporate identity. The company has officially rebranded itself as Skybitech Healthcare Limited, marking a new chapter in its corporate journey.

Key Details of the Name Change

Official Approval and Documentation

The company has received formal approval for this name change from the Registrar of Companies (ROC), Ministry of Corporate Affairs. A fresh Certificate of Incorporation has been issued to the company, reflecting its new identity as Skybitech Healthcare Limited.

Regulatory Compliance

In adherence to Regulation 30 of the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements Regulations, 2015, the company has duly informed the BSE Limited about this development. This timely disclosure ensures transparency and keeps all stakeholders informed about the significant change in the company's identity.

Implications for Stakeholders

It's important to note that while the company's name and CIN have changed, its BSE script code remains the same. This continuity in the script code should help maintain consistency for investors and traders dealing with the company's shares on the stock exchange.

Transition Period

As per regulatory requirements, Skybitech Healthcare Limited is obligated to display its old name (Kapil Cotex Limited) alongside the new name for a period of two years. This practice is mandated at all places where the company is required to display its name, in accordance with Section 12 of the Companies Act.

Stakeholder Advisory

The Ministry of Corporate Affairs has advised all stakeholders to verify the latest status of the company and its directors through the official MCA website ( www.mca.gov.in/MCA21 ). This recommendation underscores the importance of due diligence in light of the corporate changes.

This name change from Kapil Cotex Limited to Skybitech Healthcare Limited potentially signals a shift in the company's business focus or strategy. Stakeholders may want to keep a close eye on any further announcements or changes in the company's operations that might follow this rebranding exercise.